This study was designed to establish whole-exome (WES) and RNA sequencing profiles of non-small cell lung cancer (NSCLC) biosamples obtained from patients prior to immunotherapy with PD-1 or PD-L1 specific ICI therapeutics. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.